Advertisement

Supply Chain



Mylan confirmed Monday that it will complete a $1 billion share repurchase plan, which was previously approved by its board of directors.

Pfizer will end research into treatments for Alzheimer's and Parkinson's disease, resulting in the elimination of 300 positions at the company's Massachusetts facilities in Andover and Cambridge, and its Connecticut facility in Groton, reports The Wall Street Journal.

Advertisement

Most Read

Advertisement
Advertisement